In this installment of the “How I treat …” series in Blood, the authors present eight clinical vignettes of patients with acute myeloid leukemia (AML), and discuss practical approaches to comorbidities that affect clinical decision-making, especially in determining which patients are candidates for allogeneic HCT. The comorbidities discussed include cardiomyopathy and ischemic heart disease; chronic renal failure with and without dialysis; hepatitis and cirrhosis; chronic pulmonary insufficiency and cerebral vascular disease. The authors conclude that with appropriate subspecialty support, many AML patients with comorbidities can undergo HCT as a curative therapy and achieve successful long-term outcomes.
Review: How I Treat AML Patients with Preexisting Comorbidities
Jun 2016